Pathology & Oncology Research

, Volume 25, Issue 1, pp 311–318 | Cite as

The Significance of Long Non-coding RNA HULC in Predicting Prognosis and Metastasis of Cancers: a Meta-Analysis

  • Yangyang Ding
  • Cheng Sun
  • Jingrong Li
  • Linhui Hu
  • Manman Li
  • Jun Liu
  • Lianfang Pu
  • Shudao XiongEmail author
Original Article


Long non-coding RNAs (lncRNAs) have been demonstrated that they not only play important roles in tumorgenicity but also associate with cancer prognosis. Recently, highly up-regulated in liver cancer (HULC) is abnormally expressed in liver cancer and other cancers, and participated in cancers progression; however, it is unclear whether its expression is associated with prognosis. Here, we performed a meta-analysis and systematic review to evaluate the prognostic value and metastasis of HULC in various cancer patients. The meta-analysis was performed using a systematic search of PubMed, Web of Science, ScienceDirect and Wiley Online Library database to eligible studies. The pooled hazard ratios (HRs) with a 95% confidence interval (95% CI) were calculated to assess its prognosis and metastasis in human cancer. A total of 1134 patients from 11 studies were included. The results indicated that overexpression of HULC was associated with poor overall survival (OS) (HR = 1.89, 95% CI: 1.32–2.47). Furthermore, subgroup analysis showed that cancer type (digestive system cancer or non-digestive system cancers) and sample size (more or less than 100) significantly associated between HULC and OS. In addition, overexpression of HULC expression was significantly associated with metastasis in cancers (HR = 2.67, 95% CI: 0.94–4.39). The meta-analysis indicated that lncRNA HULC could serve as a new molecular marker for cancer prognosis and metastasis.


lncRNA HULC Neoplasms Prognosis Metastasis Meta-analysis 



hazard ratios


confidence interval


overall survival


colorectal cancer


gastric cancer


triple-negative breast cancer


hepatocellular carcinoma


diffuse large B-cell lymphoma


event-free survival


progression–free survival



This work was partly supported by National Science Foundation of China (81272259).

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. 1.
    Wu S, Powers S, Zhu W, Hannun YA (2016) Substantial contribution of extrinsic risk factors to cancer development. Nature 529:43–47CrossRefGoogle Scholar
  2. 2.
    Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrozek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A 111:18679–18684CrossRefGoogle Scholar
  3. 3.
    Kim SH, Lee HW, Go SI, Lee SI, Lee GW (2016) Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 7:36198–36206Google Scholar
  4. 4.
    Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ (2016) The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 265:539–546Google Scholar
  5. 5.
    Han Li C, Chen Y (2015) Small and long non-coding RNAs: novel targets in perspective cancer therapy. Curr Genomics 16:319–326CrossRefGoogle Scholar
  6. 6.
    Ulitsky I (2013) D.P. Bartel. lincRNAs: genomics, evolution, and mechanisms. Cell 154:26–46CrossRefGoogle Scholar
  7. 7.
    Kapusta A, Feschotte C (2014) Volatile evolution of long noncoding RNA repertoires: mechanisms and biological implications. Trends Genet 30:439–452CrossRefGoogle Scholar
  8. 8.
    Ylipaa A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M, Kartasalo K, Leppanen SP, Karakurt S, Seppala J, Yli-Harja O, Tammela TL, Zhang W, Visakorpi T, Nykter M (2015) Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer. Cancer Res 75:4026–4031CrossRefGoogle Scholar
  9. 9.
    Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132:330–342CrossRefGoogle Scholar
  10. 10.
    Sun X-H, Yang L-B, Geng X-L, Wang R, Zhang Z-C (2015) Increased expression of IncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol 8:2994–3000Google Scholar
  11. 11.
    Wang YF, Zhang S, Li XQ, Wang Y (2016) Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival. Eur Rev Med Pharmacol Sci 20:3987–3991Google Scholar
  12. 12.
    Yang XJ, Huang CQ, Peng CW, Hou JX, Liu JY (2016) Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression. Gene 592:172–178CrossRefGoogle Scholar
  13. 13.
    Shi F, Xiao F, Ding P, Qin H, Huang R, Long Noncoding RNA (2016) Highly up-regulated in liver cancer predicts unfavorable outcome and regulates metastasis by MMPs in triple-negative breast cancer. Arch Med Res 47:446–453CrossRefGoogle Scholar
  14. 14.
    Peng W, Wu J, Feng J (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother 79:188–193CrossRefGoogle Scholar
  15. 15.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefGoogle Scholar
  16. 16.
    Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefGoogle Scholar
  17. 17.
    Fang K, Liu P, Dong S, Guo Y, Cui X, Zhu X, Li X, Jiang L, Liu T, Magnetofection YW (2016) Based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells. Int J Oncol 49:509–518CrossRefGoogle Scholar
  18. 18.
    Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, Diederichs S (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73:1180–1189CrossRefGoogle Scholar
  19. 19.
    Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, Ye L, Zhang X (2012) Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287:26302–26311CrossRefGoogle Scholar
  20. 20.
    Zhang Y, Li Z, Zhang Y, Zhong Q, Chen Q, Zhang L (2015) Molecular mechanism of HEIH and HULC in the proliferation and invasion of hepatoma cells. Int J Clin Exp Med 8:12956–12962Google Scholar
  21. 21.
    Ma Y, Huang D, Yang F, Tian M, Wang Y, Shen D, Wang Q, Chen Q, Zhang L, Long Noncoding RNA (2016) Highly upregulated in liver cancer regulates the tumor necrosis factor-alpha-induced apoptosis in human vascular endothelial cells. DNA Cell Biol 35:296–300CrossRefGoogle Scholar
  22. 22.
    Lu Z, Xiao Z, Liu F, Cui M, Li W, Yang Z, Li J, Ye L, Zhang X (2016) Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget 7:241–254Google Scholar
  23. 23.
    Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, Sun B, Ye L, Zhang X (2015) Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res 75:846–857CrossRefGoogle Scholar
  24. 24.
    Maciel Uzan VR, Lengert AvH, Boldrini E, Penna V, Scapulatempo-Neto C, Scrideli CA, de Moraes Filho AP, Bezerra Cavalcante CE, de Oliveira CZ, Lopes LF, Vidal DO (2016) High expression of HULC is associated with poor prognosis in osteosarcoma patients. PLoS One 11:e0156774CrossRefGoogle Scholar
  25. 25.
    Li D, Liu X, Zhou J, Hu J, Zhang D, Liu J, Qiao Y, Zhan Q, LncRNA HULC (2016) Modulates the phosphorylation of YB-1 through serving as a scaffold of ERK and YB-1 to enhance hepatocarcinogenesis. Hepatology 65:1612–1627CrossRefGoogle Scholar
  26. 26.
    Yu X, Zheng H, Chan MT, Wu WK (2016) HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med 21:410–417Google Scholar
  27. 27.
    Yang Z, Lu Y, Xu Q, Tang B, Park CK, Chen X (2015) HULC and H19 played different roles in overall and disease-free survival from hepatocellular carcinoma after curative hepatectomy: a preliminary analysis from gene expression omnibus. Dis Markers 2015:191029Google Scholar
  28. 28.
    Li S-P, Xu H-X, Yu Y, He J-D, Wang Z, Xu Y-J, Wang C-Y, Zhang H-M, Zhang R-X, Zhang J-J, Yao Z, Shen Z-Y, LncRNA HULC (2016) Enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7:42431–42446Google Scholar
  29. 29.
    Yan H, Tian R, Zhang M, Wu J, Ding M, He J (2017) High expression of long noncoding RNA HULC is a poor predictor of prognosis and regulates cell proliferation in glioma. Onco Targets Ther 10:113–120CrossRefGoogle Scholar
  30. 30.
    Jin C, Shi W, Wang F, Shen X, Qi J, Cong H, Yuan J, Shi L, Zhu B, Luo X, Zhang Y, Long SJ (2016) Non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget 7:51763–51772Google Scholar
  31. 31.
    Peng W, Gao W, Feng J (2014) Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 31:346CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Yangyang Ding
    • 1
  • Cheng Sun
    • 2
  • Jingrong Li
    • 3
  • Linhui Hu
    • 1
  • Manman Li
    • 1
  • Jun Liu
    • 1
  • Lianfang Pu
    • 4
  • Shudao Xiong
    • 1
    Email author
  1. 1.Department of Hematology/Hematological LabThe Second Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China
  2. 2.Department of PharmacologyThe Second Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China
  3. 3.Department of EmergencyThe Second Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China
  4. 4.Department of HematologyThe Third People’s Hospital of BengbuBengbuPeople’s Republic of China

Personalised recommendations